Allscripts announces second quarter 2017 results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/25/2026
- Nasdaq lags on angst over AI spending ahead of earnings reports
- Elon Musk’s trillion-dollar meltdown: How SpaceX and Tesla erased $700 billion
- Intel jumps 10% after AI-fueled quarter crushes estimates, upbeat outlook
- Oil falls on report China pushing for end US-Iran war
- Why Meta, Microsoft, and Nvidia are championing open-weight AI
- AMD (AMD) PT Raised to $1,250 at Baird
- Pakistan, Iran explore path towards new talks with US in a China-initiated push, sources say
- FDA approves Tylenol with Naproxen as first OTC combo pain reliever
- Elon Musk’s trillion-dollar meltdown: How SpaceX and Tesla erased $700 billion
- Outlook Therapeutics (OTLK) halted, news pending
Allscripts (MDRX) Reports In-Line Q2 EPS
August 3, 2017 4:04 PM EDTAllscripts (NASDAQ: MDRX) reported Q2 EPS of $0.15, in-line with the analyst estimate of $0.15. Revenue for the quarter came in at $428 million versus the consensus estimate of $425 million.
For earnings history and earnings-related data on Allscripts (MDRX) click here.
... More